Healthy Clinical Trial
Official title:
The Effects of Dexmedetomidine on Myocardial Repolarization in Children
Dexmedetomidine is a sedative drug that is commonly used to improve calmness and reduce pain in children waking up after surgery. Some of the side effects of dexmedetomidine, such as a potential change in how the heart muscles contract and changes in blood sugar and potassium levels, are poorly understood. The current study aims to examine these changes directly in healthy children undergoing elective surgery by measuring the heart beats (with an electrocardiogram) and blood sugar and potassium at specific times before and after dexmedetomidine is given. The investigators aim to establish a better understanding of this drug's safety profile.
Purpose:
This study is being conducted to evaluate the effect of three different doses of
dexmedetomidine (Precedex® , Hospira Healthcare) on myocardial repolarization, and blood
glucose and potassium levels in children undergoing elective surgery.
Hypotheses:
The investigators hypothesize that administering a dexmedetomidine bolus will have some
effect on myocardial repolarization, blood glucose, and potassium concentrations in a
dose-dependent manner, whereas a saline bolus will not.
Justification:
Dexmedetomidine is a potent, centrally acting α-2 adrenoreceptor agonist with sympatholytic,
sedative, amnestic, anxiolytic and analgesic effects, which properties make it popular for
use in both pediatric anesthesia and intensive care. In 2013, dexmedetomidine was added to
the "possible risk factor for torsades de pointes (TdP)" drug list on crediblemeds.org.
Clinicians are currently advised to be vigilant about potential QT prolongation with
dexmedetomidine, especially in patients with congenital long QT syndrome (LQTS). However,
current evidence for dexmedetomidine-induced prolonged QT is sparse and somewhat
contradictory, and the effect of dexmedetomidine on the Tp-e interval has yet to be reported
in detail in adults or children. Another poorly defined pharmacodynamic effect of
dexmedetomidine is its effect on blood glucose concentration. Theoretically, dexmedetomidine
would be expected to cause hypoinsulinaemia and a resultant increase in blood glucose levels
(hyperglycemia). Previous studies are in contrast to this however; with reports of
hypoglycemia after large doses of the drug. Considering the use of dexmedetomidine in
pediatric anesthesia, pediatric intensive care and its increasing use in the neonatal
population, increased knowledge of the effect of dexmedetomidine on blood glucose would be
valuable.
Finally, hypokalemia is listed as a treatment-emergent adverse event occurring in >2% of
adult patients receiving dexmedetomidine in long-term intensive care unit sedation studies.
The effect of dexmedetomidine on serum potassium levels in healthy children has yet to be
elucidated. Given that hypokalemia increases the risk of TdP, and that there is a possibility
that dexmedetomidine may be torsadogenic, this effect is also worthy of investigation.
In sum, the use of dexmedetomidine is associated with many clinical benefits, but its effects
on indices of myocardial repolarization, as well as its effects on glucose and potassium
metabolism, remain poorly understood and need to be better defined in order to use this drug
safely and effectively.
Objectives:
The primary objective of this study is to investigate the effects of three different doses of
dexmedetomidine (0.25/0.5/0.75 mcg/kg) on indices of myocardial repolarization (QTc and Tp-e
intervals). As a secondary objective, this study will also sample blood glucose and potassium
levels before and after dexmedetomidine administration to ascertain if there is any
significant effect of a single bolus dose on blood glucose concentrations.
Research Method:
The investigators propose a randomized, single-blinded, 4-group comparative study to
characterize the effects of different doses of dexmedetomidine on myocardial repolarization
and blood glucose levels in healthy children undergoing elective surgery. The study-specific
interventions will include giving a bolus of dexmedetomidine (0.25/0.5/0.75 mcg/kg; or 10mL
saline) after induction of general anesthesia, recording two 12-lead ECGs (one before and one
after dexmedetomidine administration), and taking three venous blood samples (one before and
two after dexmedetomidine administration) to measure glucose and potassium. If the
anesthetist would like to administer dexmedetomidine to a participant in the control (saline)
group as part of their normal practice, they can do so after the study period is over (after
the last blood sample).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |